Review

Targeted Oncology

, Volume 7, Issue 2, pp 99-106

First online:

New targeted agents in gastroenteropancreatic neuroendocrine tumors

  • Marta BenaventAffiliated withDepartment of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [HUVR, CSIC, Universidad de Sevilla]
  • , Maria Jose de MiguelAffiliated withDepartment of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [HUVR, CSIC, Universidad de Sevilla]
  • , Rocio Garcia-CarboneroAffiliated withDepartment of Medical Oncology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS) [HUVR, CSIC, Universidad de Sevilla] Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Neuroendocrine carcinomas are rare neoplasms although of increasing incidence and concern. While traditionally considered of indolent nature, once they progress beyond surgical resectability, the outcome is ultimately fatal for the majority of patients. Somatostatin analogs are useful to control symptoms in functioning tumors and may slow tumor progression in certain disease settings, but sensitivity to conventional cytotoxic chemotherapy is rather limited. In this context, results of the recently published randomized trials with sunitinib and everolimus have demonstrated for the first time that there are agents able to positively impact on the natural history of this complex disease. In this review, we will discuss available data on angiogenesis and mammalian target of rapamycin inhibitors for the treatment of advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.

Keywords

Targeted agents Neuroendocrine Gastroenteropancreatic Therapy Everolimus Sunitinib